drugset

drugset / Trial / NCT00099801

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

NCT00099801 ↗

Phase 3 Completed Novartis Pharmaceuticals

RandomizedParallel-groupOpen-labelTreatment

Summary

The safety and efficacy of FTY720 is being evaluated in patients who receive a kidney transplant.

Timeline

Start: 2005-01
Primary completion: 2006-03
Completion: 2006-03

Publications

Results Saab G, Almony A, Blinder KJ, Schuessler R, Brennan DC. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch Ophthalmol. 2008 Jan;126(1):140-1. doi: 10.1001/archophthalmol.2007.23. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fingolimod	Small molecule	—	—

Indications

No indication recorded.